Company intelligence / Profile preview

Primo Scientific

Taipei City, Taipei City, Taiwanprimobt.com ↗

Ownership: Private
Development stage: Other

Overview

Primo Biotechnology develops novel radioligand theranostics and molecular imaging platforms focused on precision diagnosis and treatment of cancers. Their technology enables non-invasive detection of early-stage cancers such as colorectal, esophageal, lung adenocarcinoma, and prostate cancer. They have presented preclinical/early clinical data at scientific conferences in Taiwan.

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalSmall moleculePeptides
Industry: Biotech

Partnerships

No major pharmaceutical partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Primo Scientific.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Primo Scientific.

Explore the full profile